Plus de 100 pays participent ce mardi à un sommet sur le climat, en marge de l'Assemblée générale de l'ONU, afin de présenter leurs objectifs de réduction des émissions à l'horizon 2035. À moins de deux mois de la COP30, seuls 40 pays ont soumis leurs plans. Les Etats-Unis, dont le président s'est illustré par un discours climatosceptique la veille, n'y participent pas. La Chine, premier pollueur mondial, doit également dévoiler ses ambitions, alors que l'UE déçoit sur ses ambitions climatiques.

Jonathan - Gasworks - repair.This show was broadcast on OAR 105.4FM Dunedin - http://oar.org.nz and made thanks to the support of NZ on Air.

S2 Ep 02 - Jonathan - Gasworks - repair This show was broadcast on OAR 105.4FM Dunedin - http://oar.org.nz and made thanks to the support of NZ on Air.

Bisimillah mon ka taskaraam men Kiwal Taariindi. Hannde kaalaten ko e alhaali caɗeele kaɓɓodiiɗe e diƴƴe ɗe laaɓaanikam e diƴƴe toɓo e nder gure mawɗe afrikiyankooje. Hoɓɓe men heen ko Kadiata Barry DIALLO, tawaaɗo e mojobere wi'eteende "Guinée écologie" daroniinde ndeenka taariindi to Guinée e Salif Baydal BA, heertorɗo Kiwal Taariindi to rewo Senegal.

Dan Kaiser and Brad Carlson continue their discussion on N-fixing biostimulant products in today's episode of the Advancing Nitrogen Smart Podcast. What's the most up-to-date working definition of a crop biostimulant? On which crops are N-fixing products typically used? What is NCERA103.org, and in what ways it it a useful resource for farmers and other agricultural professionals? What are some

Previsioni meteo Toscana del 24-9-2025

Previsioni meteo Toscana del 24-9-2025

Ikgadējā Zinātnieku nakts šogad aicina atklāt sevī pētnieka gēnu un piedalīties dažādu augstskolu un institūtu sarūpētajās aktivitātes. Vienlaikus iegūti jaunākie monitoringa dati par sabiedrības uzticēšanos zinātnei. Ko liecina šis pētījums, kāda ir zinātnieku saziņa ar sabiedrību un kādas atziņas ir pašiem pētniekiem par komunikāciju ar sabiedrību? Raidījumā Zināmais nezināmajā analizē Latvijas hidroekoloģijas institūta pētniece, Jūras monitoringa nodaļas Hidrobioloģijas laboratorijas

عناوين النشرة العلمية : - ابتكار أصغر محرّك على رقاقة في التاريخ حصل بتصميم من جامعة غوتنبرغ السويدية - الجيل السادس التجريبي من شرائح الاتّصال ظهر في الصين   - الأبحاث المرتبطة بالزهايمر بين تقدّم محدود وجدالات محتدمة بشأن العلاجات المتوفّرة في إنجاز غير مسبوق استغرق العمل على تطويره أكثر من ثلاثين عاما، ابتكر فيزيائيون اختصاصيون في فيزياء المواد الرخوة من جامعة Gothenburg  في السويد أصغر محرك على رقاقة في التاريخ إذ أن حجم هذا المحرّك المتناهي الصغر يسمح بوضعه داخل شعرة بشرية. المحرّك أو Gear

Discover how storytelling supports positive humanism by fostering empathy, ethical reflection, and personal growth within a secular worldview.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for

在斯坦福大学David Furman博士眼中，衰老像是一场免疫系统与时间的拉锯战。举家搬进森林，3年逆生长10岁？斯坦福David Furman博士：炎性衰老可测可控！

Show notes at pharmacyjoe.com/episode1062. In this episode, I’ll discuss hemodynamic changes after using a dexmedetomidine loading dose in ED patients.The post 1062: Hemodynamic changes after using a dexmedetomidine loading dose in ED patients appeared first on Pharmacy Joe.

Guest: David Majure, M.D., MPH On this episode of Advances in Care, host Erin Welsh talks to Dr. David Majure, a cardiologist and heart failure specialist at NewYork-Presbyterian and Weill Cornell Medicine. Together, they discuss the rapid rise in GLP-1 research over the past few years, indicating new applications for these therapies to help a wide variety of patients. They explore how GLP-1s work on a molecular level and how using them to treat diabetes revealed other potential

Guest: Leonard H. Calabrese, DO Preventing serious infections should be a priority when treating patients with immune-mediated inflammatory diseases, especially those receiving immunosuppressive therapies. By assessing patients’ level of immunocompetence, clinicians can better tailor vaccination strategies and optimize infection prevention. Hear Dr. Leonard Calabrese discuss how to evaluate immunosuppression risk and coordinate timely vaccinations for patients undergoing

Guest: Joan Merrill, MD Despite common misconceptions, lupus nephritis is part of a broader immune imbalance seen in systemic lupus, not a separate condition. This is why it's important to shift focus from organ-specific treatment to immune dysregulation targeting. Hear Dr. Joan Merrill, Professor at the Oklahoma Medical Research Foundation’s Arthritis and Clinical Immunology Research Program in Oklahoma City, discuss the spectrum of lupus and, based on that, considerations for

Despite advances in lipid-lowering therapies, disparities in hyperlipidemia diagnosis and treatment persist. Dr. Keith Ferdinand examines how social drivers of health impact access, adherence, and outcomes and explains how clinicians can help address gaps in care for underserved populations. Dr. Ferdinand is a Professor of Medicine as well as the Gerald S. Berenson Chair in Preventative Cardiology and Director of Preventative Cardiology at Tulane University School of Medicine in New

Effective management of hyperlipidemia requires tailoring treatment to a patient’s cardiovascular risk profile. Lifestyle modification remains the cornerstone of care, while high-risk patients often require pharmacotherapy. Dr. Keith Ferdinand shares evidence-based strategies for reducing LDL and addressing comorbidities while engaging patients in shared decision making. Dr. Ferdinand is a Professor of Medicine as well as the Gerald S. Berenson Chair in Preventative Cardiology and Director